Unknown

Dataset Information

Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis.


ABSTRACT:

Importance

New therapeutic classes of migraine-specific treatment have been developed, including 5-hydroxytryptamine1F receptor agonists (lasmiditan) and calcitonin gene-related peptide antagonists (rimegepant and ubrogepant).

Objective

To compare outcomes associated with the use of lasmiditan, rimegepant, and ubrogepant vs triptans for acute management of migraine headaches.

Data sources

The Cochrane Register of Controlled Trials, Embase, and PubMed were searched from inception to March 5, 2020.

Study selection

Double-blind randomized clinical trials examining current available migraine-specific acute treatments were included.

Data extraction and synthesis

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline was appl

SUBMITTER: Yang CP 

PROVIDER: S-EPMC8506232 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature